Market Overview

UPDATE: Deutsche Bank Downgrades Sarepta Therapeutics Following FDA Announcement That NDA Filing is Premature

Sarepta Says FDA Postpones Advisory Committee Meeting to Review Eteplirsen Due to Severe Weather Storm in the Washington D.C.

In a report published late Tuesday, Deutsche Bank analyst Robyn Karnauskas downgraded the rating on Sarepta Therapeutics (NASDAQ: SRPT) from Buy to Hold, and lowered the price target from $71.00 to $17.00.

In the report, Deutsche Bank noted, “Sarepta announced that the FDA now says NDA filing is premature and that they want a placebo controlled trial that could delay a launch. We are downgrading the stock and see increased risk due to uncertainty on design and timelines and have reduced the prob. of success. We still believe in the technology but wait for more clarity. We continue to see SRPT as a long term technology play but right now there are questions beyond that.”

Sarepta Therapeutics closed on Tuesday at $13.05.

Posted-In: Deutsche Bank Robyn KarnauskasAnalyst Color Downgrades Analyst Ratings


Related Articles (SRPT)

View Comments and Join the Discussion!